Don't Wait for the Ginkgo Bioworks IPO to Profit from This $3 Billion Industry

After making Forbes list for the next billion-dollar startup, anxious investors are hoping a Ginkgo Bioworks IPO is in the works. That's because biotech and healthcare IPOs are netting investors gains as much as 300% so far in 2017. Here are all the details about Ginkgo, as well as a special profit opportunity forming in the $3 trillion healthcare industry... Tags: IPOs To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2017 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Don't Wait for the Ginkgo Bioworks IPO to Profit from This $3 Billion Industry appeared first on Money Morning - We Make Investing Profitable .